Latest Capital Raising News

Energy Technologies Limited has secured nearly $2 million through a discounted share placement aimed at reducing debt and shoring up working capital amid ongoing financial restructuring.

Eden Innovations attributes recent share price rise to an upcoming US defence forum presentation, confirming no undisclosed material information.

Asara Resources has raised $60 million through a strongly supported institutional placement to fast-track drilling and development at its flagship Kada Gold Project in Guinea.

Motio Ltd has marked a turning point with its first net profit, record sales activity, and a 13% increase in forward revenue, signaling a shift to scalable growth.

Taiton Resources has finished drilling a single 810m diamond hole at its Yogi prospect within the Highway Project, South Australia, with assay results due in June.

Aquirian Limited has secured $8 million through a strongly supported placement to accelerate growth of its Drillforce business and support a major $48 million contract at the Lord Byron mine.

Regener8 Resources has closed its entitlement offer, raising $1.42 million to fund the acquisition and exploration of its Srebrenica North Project, with new shares set to begin trading next week.

Murray Cod Australia (ASX:MCA) has launched the retail tranche of its fully underwritten $18.6 million entitlement offer at a 43% discount, aiming to convert its record 3,700-tonne biomass into cash and expand processing capacity.

Finder Energy has completed the first tranche of its $33 million capital raise, issuing 42 million shares at 50 cents each to institutional and professional investors. The company will seek shareholder approval in June for a second tranche involving 12 million more shares.

Neometals is pivoting towards gold production with a funded JV at its Barrambie Ironclad deposit, while simultaneously progressing a substantial lithium-potash brine project in Utah.

Hartshead Resources has sent its Scheme Booklet to shareholders detailing ACAM GP Limited's proposed $40 million acquisition at a significant premium. The Board unanimously backs the all-cash offer, with a shareholder meeting set for 8 June 2026.

Vectus Biosystems appoints Dr Tara Speranza as CEO and CTO to accelerate development of lead fibrosis drug VB0004 with performance-linked incentives.